Lung Cancer

Clinical Trial Results of Ramucirumab in Squamous NSCLC

Monoclonal Antibodies in Squamous Cell Lung Cancer

Treatment Options for Relapsed Squamous NSCLC

Maintenance Therapy in Squamous NSCLC

Nab-Paclitaxel plus Carboplatin in Squamous NSCLC

Optimal Chemotherapy for Squamous NSCLC

Mutation Testing and Lung-MAP Clinical Trial

Mutational Landscape of Squamous NSCLC

Clinical Presentation of Squamous NSCLC

Tremelimumab Misses OS Endpoint in Phase IIb Mesothelioma Trial

By Silas Inman

March 1st 2016

Second- or third-line treatment with tremelimumab monotherapy failed to improve overall survival compared with placebo for patients with unresectable malignant mesothelioma.

Peregrine Stops Phase III Trial of Bavituximab in NSCLC

By Silas Inman

February 26th 2016

The phase III SUNRISE trial comparing bavituximab plus docetaxel with docetaxel and placebo for patients with nonâ€“small cell lung cancer has been halted following a futility analysis.

Expert Discusses Translating EGFR Mutation Status Into Action in NSCLC

By Jane de Lartigue, PhD

February 24th 2016

Mark Socinski, MD, discusses the three generations of drugs are now available to treat patients with EGFR-mutant nonâ€“small cell lung cancer, and mutation testing for patients diagnosed with advanced or metastatic disease has been incorporated into clinical practice guidelines.

Dr. Filosso on Future of Treating Patients With Lung NETs

By Pier Luigi Filosso, MD

February 16th 2016

Pier Luigi Filosso, MD, associate professor of Thoracic Surgery, University of Torino, Italy, discusses future approaches to treating patients with neuroendocrine tumors of lung origin.

Immunotherapy Continues Rapid Advance in NSCLC

By Laura Panjwani

February 16th 2016

Naiyer Rizvi, MD, discusses the role of PD-L1 testing, which PD-1/PD-L1 agents have the most potential, and what is on the horizon for the use of immunotherapies in non-small cell lung cancer.

Dr. Martins on Patient Selection for Nivolumab in NSCLC

By Renato G Martins, MD, MPH

Combining Therapies with Antiangiogenic Antibodies

Renato G. Martins, MD, MPH, medical director, Outpatient General Oncology/Hematology, Thoracic/Head and Neck Oncology, Seattle Cancer Care Alliance, professor, University of Washington School of Medicine, discusses patient selection for nivolumab (Opdivo) as a treatment for patients with nonâ€“small cell lung cancer (NSCLC).

Ramucirumab for Squamous or Nonsquamous Lung Cancer

Use of Bevacizumab for Lung Cancer

Therapeutic Targeting Against Abnormal Tumor Vasculature

Dysregulated Angiogenesis in Cancer

PD-L1/CTLA-4 Dual Blockade Shows Promise in NSCLC

By Jason M. Broderick

February 12th 2016

A combination checkpoint blockade with the PD-L1 inhibitor durvalumab and the antiâ€“CTLA-4 agent tremelimumab induced a response rate of 23% in patients with advanced nonâ€“small cell lung cancer.

FDA Schedules ODAC Meeting for Rociletinib in NSCLC

By Silas Inman

February 12th 2016

The FDA has scheduled an ODAC advisory hearing for April 12, 2016, to discuss the new drug application for rociletinib as a treatment for patients with metastatic EGFR T790M-mutated nonâ€“small cell lung cancer.

Sequencing of Therapies in EGFR-Mutant NSCLC

Mechanisms of Resistance to Upfront EGFR-Targeted Therapy

EGFR Mutations and Targeted Therapy in NSCLC

EGFR TKIs for Upfront Treatment of NSCLC

Pembrolizumab Emerges as a Potent Treatment in NSCLC

By Edward B. Garon, MD, MS